MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):72-76. doi: 10.15585/mmwr.mm6903a4.
Infants are at increased risk for pertussis-associated morbidity and mortality, and pregnant women and their infants are more likely than other patient populations to experience severe influenza-related illness (1,2). The Advisory Committee on Immunization Practices (ACIP) recommends that all women receive the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during each pregnancy, preferably during the early part of gestational weeks 27-36 (3). ACIP also recommends that women who are or might be pregnant during the influenza season receive the inactivated influenza vaccine at any time during pregnancy (4). Despite these recommendations, coverage with Tdap and influenza vaccines during pregnancy has been low, with approximately one half of women receiving each vaccine and only one third receiving both, based on a survey during March-April 2019 (5). Data obtained through a retrospective chart review of randomly selected pregnant women who delivered at the University of Florida Health Shands Hospital in Gainesville, Florida, from January 1, 2016, to December 31, 2018, were analyzed to assess vaccination coverage by insurance type. Because the Florida Medicaid policy at that time did not cover these vaccines during pregnancy, the hospital system offered Tdap and influenza vaccines at no additional cost to mothers during the immediate postpartum hospital stay. Among 341 women, 68.6% of privately insured and 13.4% with Medicaid received Tdap during pregnancy, and among 316 women, 70.4% of privately insured and 35.6% with Medicaid received influenza vaccine during pregnancy. Many women, especially those with Medicaid, were vaccinated in the immediate postpartum period, when vaccination was available at no cost, increasing Tdap vaccination rates to 79.3% for privately insured and 51.7% for women with Medicaid; influenza vaccination rates rose to 72.0% for privately insured and 43.5% for women with Medicaid. These data suggest that the state Medicaid policy to not cover these vaccines during pregnancy might have significantly reduced coverage among its enrollees.
婴儿患百日咳相关发病率和死亡率的风险增加,孕妇及其婴儿比其他患者群体更容易患严重的流感相关疾病(1,2)。免疫实践咨询委员会(ACIP)建议所有女性在每次怀孕期间接种破伤风类毒素、白喉类毒素和无细胞百日咳(Tdap)疫苗,最好在妊娠 27-36 周的早期(3)。ACIP 还建议在流感季节期间可能怀孕或已经怀孕的女性在怀孕期间的任何时间接种灭活流感疫苗(4)。尽管有这些建议,但根据 2019 年 3 月至 4 月的一项调查,怀孕期间 Tdap 和流感疫苗的接种率一直很低,大约有一半的女性接种了这两种疫苗,只有三分之一的女性接种了这两种疫苗(5)。通过对佛罗里达州盖恩斯维尔市佛罗里达大学健康山兹医院随机选择的分娩孕妇进行回顾性病历审查获得的数据进行了分析,以评估按保险类型划分的疫苗接种率。由于当时佛罗里达州医疗补助计划不涵盖怀孕期间的这些疫苗,医院系统在产妇产后立即住院期间免费向母亲提供 Tdap 和流感疫苗。在 341 名女性中,有 68.6%的私人保险和 13.4%的医疗补助获得了 Tdap 疫苗,在 316 名女性中,有 70.4%的私人保险和 35.6%的医疗补助获得了流感疫苗。许多女性,尤其是那些享受医疗补助的女性,在产后立即接受了疫苗接种,当时疫苗是免费提供的,这使得私人保险的 Tdap 接种率提高到 79.3%,享受医疗补助的女性提高到 51.7%;流感疫苗接种率分别上升至 72.0%和 43.5%。这些数据表明,该州医疗补助计划在怀孕期间不涵盖这些疫苗可能大大降低了其参保者的覆盖率。